Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

This systematic review reported that among men taking finasteride for benign prostatic hyperplasia, total PSA levels decreased by 30% to 50%, and free PSA by up to 45%, with reductions in prostate volume and PSA density observed as well.

Baseline PSA levels affect general health and sexual satisfaction in men with BPH treated with finasteride or placebo.

This study found that serum PSA levels are higher in hirsute women and can be significantly reduced by antiandrogen treatment, suggesting PSA as a marker of androgen action in females.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

In this study, the combination of Serenoa repens extract with Phenolmicin P3 and Bosexil suppositories significantly improved lower urinary tract symptoms and decreased PSA levels in patients with benign prostatic obstruction-related symptoms.

In this study, higher urethral prostate-specific antigen (urPSA) levels in men after radical prostatectomy were associated with higher androgenic alopecia scores and higher postoperative PSA.

This review discusses how 5α-reductase inhibitors affect PSA levels in benign prostatic hyperplasia treatment and their role in prostate cancer screening, but reports no new clinical findings.

This study found that men with vertex baldness had higher serum dihydrotestosterone levels compared to those with frontal baldness, suggesting different hormonal profiles between these two groups in androgenetic alopecia.

This study found that both finasteride and dutasteride reduced the risk of prostate cancer detection, but finasteride was associated with an increased diagnosis of higher-grade disease, unlike dutasteride.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

This study found that finasteride 1 mg daily decreased 5alpha-dihydrotestosterone levels and improved hair growth in younger men with androgenetic alopecia, with higher initial hormone levels predicting better response.

This study found that women with polycystic ovary syndrome had significantly higher levels of prostate-specific antigen, which positively correlated with testosterone levels, the LH/FSH ratio, and hirsutism severity.

This study examined serum PSA levels in women with androgenetic alopecia to evaluate their potential as a marker for androgen effects on target organs.

This study found that among men over 70, certain genetic variants associated with skin pigmentation affect serum PSA levels, with implications for how sun sensitivity and exposure may influence prostate cancer risk.

This study found that men with androgenetic alopecia had higher serum levels of testosterone and DHT compared to controls, suggesting a significant role of serum androgens in AGA development and progression.

This study found that metformin, insulin, and ACE inhibitors were associated with lower PSA levels, but statins did not decrease PSA, whereas low dose finasteride (1 mg) reduced PSA levels similarly to the higher 5 mg dose.

This study showed that men with androgenetic alopecia had higher serum levels of testosterone and DHT compared to controls, but no difference in PSA levels.

This study found no correlation between serum PSA levels and the severity of androgenetic alopecia at baseline in men.

This study found that the 4Kscore model, when adjusted for kallikrein marker changes due to finasteride use, improved the prediction of high-grade prostate cancer compared to adjusted total PSA alone in men taking 5-α-reductase inhibitors.

This study found that metformin is inversely associated with serum PSA levels in a dose-dependent manner, suggesting further research is needed on its potential impact on prostate cancer progression.

This study found that in 45-year-old German men, the use of metformin, insulin, and ACE inhibitors was associated with lower PSA levels, while low dose finasteride resulted in notable PSA decrease.

No link found between hair loss severity and PSA levels in men.

IL-17 inhibitors are more effective than methotrexate in preventing psoriatic arthritis in psoriasis patients.

In this study, significantly fewer men treated with finasteride for moderate to severe BPH symptoms experienced acute urinary retention or required subsequent BPH-related surgery compared to placebo-treated patients.

This study found that 5‐α‐reductase inhibitors reduce the risk of being diagnosed with prostate cancer in men who undergo regular screening, but increase the risk of sexual and erectile dysfunction.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This study found that men aged 50 and older with clinical benign prostatic hyperplasia have a significantly higher prevalence of metabolic syndrome than those without the condition in the UK primary care population.